Key points are not available for this paper at this time.
Our findings contribute to the understanding of the natural history of SMA type III and will be helpful in the interpretation of the real-world data of patients treated with commercially available drugs. ANN NEUROL 2020;88:1109-1117.
Coratti et al. (Wed,) studied this question.